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Abstract 
The overall objectives of Pharmacovigilance 
include early identification of potential safety 
hazards, evaluation, monitoring and where 
appropriate, implementation of regulatory action to 
maximise benefits and minimise risks associated 
with medicinal products. Reporting of an ADR 
associated with use of a medicinal product as well 
as medication errors is an essential source of 
necessary information that is required to achieve 
these objectives. Safety concerns that arise from 
spontaneous reporting contribute to assessment of 
the risk benefit balance and hence lead to a 
regulatory action which could be suspension or 
revocation of marketing authorization of the 
product or change in the product information. 
Furthermore, these safety concerns can be 
communicated to healthcare professionals through 
Direct Healthcare Professional Communications 
(DHPCs) and safety circulars and they form the 
basis of designing Risk Minimisation Measures 
(RMMs).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The establishment of a functional ADR 
reporting system by law since 2004, not only 
facilitates participation in the national and EU 
regulatory process, but also enables Malta to 
participate in the WHO Programme for 
International Drug Monitoring, both by contributing 
to and obtaining data from this extensive 
information resource. 
 
Mesh Terms 
Adverse Drug Reaction, Pharmacovigilance, 
Safety, Risk assessment 
 
Introduction 
All medicinal products in the EU including 
Malta are subject to strict testing and assessment of 
their quality, efficacy and safety before being 
authorised. Once placed on the market they 
continue to be monitored to assure that any aspect 
which could impact the safety efficacy profile of a 
medicine is detected and assessed and regulatory 
measures are taken as necessary. This continuous 
monitoring of the safety profile of a medicinal 
product is a core objective of Pharmacovigilance 
system. The ADR reporting system is an integral 
part of the Malta Medicines Authority’s (MMA) 
Pharmacovigilance system through which post 
marketing data about medications are collected and 
processed to aid in the surveillance and regulation 
of medicinal products. The Aim of this review is to 
disseminate the science of pharmacovigilance 
amongst Maltese doctors and to encourage 
reporting. 
 
The definition of ADR in the EU  
Directive 2001/83/EC, defines an ADR as: A 
response to a medicinal product which is noxious 
and unintended, adverse drug reaction may arise 
from the use of the product within or outside the 
terms of the marketing authorisation or from the 
occupational exposure, conditions of use outside the 
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marketing authorisation include off-label use, 
overdose, misuse, abuse and medication errors. 
There are multiple synonyms for an ADR: 
suspected adverse (drug) reaction, adverse effect, 
and undesirable effect.1 
A serious adverse reaction is an adverse 
reaction which either 
• Results in death  
• or is life threatening  
• or requires in-patient hospitalisation  
• or prolongation of existing hospitalisation  
• or results in persistent or significant disability 
or incapacity or a congenital anomaly/birth 
defect. 1 
The ADR reporting system established in 
Malta is consistent with European and Maltese 
legislation for the regulation of medicinal products 
which directs competent authorities in member 
states to establish a Pharmacovigilance system 
where this system shall be used to collect 
information useful for the surveillance of medicinal 
products, with particular reference to adverse 
reactions in human beings and to evaluate such 
information scientifically.’2-3 
In November 2003 the Maltese Medicines Act 
was published which established the regulatory 
framework for the MMA and lead further to the 
development of Pharmacovigilance subsidiary 
regulations.3 As part of the EU network, the MMA 
actively participates in the EU fora (as Rapporteur) 
to carry out the necessary regulatory actions 
mandated by law to suspend or revoke an 
authorization to place a medicinal product on the 
market where that product proves to be harmful in 
the normal conditions of use, or where therapeutic 
efficacy is lacking, or where qualitative and 
quantitative composition is not declared.’2 
 
The Role of Health Care Professionals  
In all countries where Pharmacovigilance 
systems operate, the role of healthcare professionals 
is essential in recording and reporting suspected 
ADRs they observe in their practice in order to alert 
regulatory agencies to new or emerging safety 
concerns which facilitates timely and appropriate 
regulatory action to be taken. The Maltese 
legislation on Pharmacovigilance specifies that: It 
shall be the duty of doctors and other healthcare 
professionals to report to the Authority any 
suspected serious or unexpected adverse reaction to 
a medicinal product.3 National competent 
authorities are also obliged to ‘take all appropriate 
measures to encourage doctors and other 
healthcare professionals to report suspected 
adverse reactions to the competent authorities.’2 To 
achieve this goal the MMA has adopted a 3 year 
(2016-2018) strategy plan to promote ADR 
reporting from healthcare professionals which 
involves the organisation of educational seminars 
and promotional materials to increase awareness of 
ADR reporting nationally. 
 
How to Report 
For the purposes of reporting, an ADR 
reporting form has been developed and validated. In 
2015, a unified form was designed which combines 
reporting of ADRs and medication errors whether 
they were associated with an ADR or not. 
Submission of a report does not mean an admission 
of guilt, the information contained in reports are 
entered in the MMA’s database in a secure manner 
and details of the reporter are destroyed following 
transmission to the European database 
(Eudravigilance).4 ADR report forms can be 
downloaded from MMA’s website: 
www.medicinesauthority.gov.mt/adrportal. 
The minimum criteria for a valid ADR report is: an 
identifiable reporter (e.g. doctor, pharmacist, 
dentist), identifiable patient (initials or age or date 
of birth or sex); a suspected medicinal product and a 
suspected ADR. However, a report should provide 
as much information as possible in order to 
facilitate evaluation e.g. for biological medicinal 
products ADRs should be reported by brand names 
and batch number ensuring the traceability. During 
the process MMA might request further information 
regarding individual ADR reports as appropriate.  
 
How to fill ADR form: 
The ADR form is composed of three sections 
where each section has to be filled by the reporter. 
Section 1 is to be filled when reporting an ADR; 
section 2 to be filled only when reporting a 
medication error while section 3 is for the reporter’s 
details that are requested for contacting the 
healthcare provider for further follow up. If a 
medication error resulted in an ADR then both 
sections 2 and 3 have to be filled in by the reporter. 
A detailed guidance and instructions on how to fill 
in each section can be found at the end of the report. 
Submitting a report in a timely manner along 
with the best possible quality of data within the 
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report is essential for efficient causality assessment. 
The higher the accuracy of the provided data the 
more the results of an assessment will be valid. 
Therefore, including the start and stop dates of an 
ADR and the drug treatment in terms of dd/mm/yy 
is more granular than in terms of mm/yy. 
Furthermore, availability of relevant therapeutic 
measures and laboratory data at baseline, during 
therapy, and subsequent to therapy, including blood 
levels, will facilitate decisions on the causal relation 
between an ADR and the suspected medications, 
e.g. a laboratory test measuring biochemical or an 
immunologic marker might be helpful to explain 
the suspected adverse drug effect.5 
 
What and When to report 
Healthcare professionals are encouraged to 
report all suspected ADRs to MMA. It is not 
necessary to be certain of the casual relationship 
between an ADR and a medicinal product to report, 
but by keeping vigilance for signs and symptoms 
that may enhance or exclude the possibility of a 
medicine-induced reaction as well as following up 
the patient enables the reporter to provide the 
necessary information for regulators and marketing 
authorisation holder (MAH) to interpret the case, 
evaluate the safety issues at hand and act 
accordingly if required.6 
All suspected ADRs to all drugs and vaccines 
must be reported.  Although it is highly significant 
to identify previously unrecognised side effects, it is 
also important to emphasise the fact that well-
known ADRs (particularly serious or severe) of 
established medicines (e.g. gastrointestinal bleeding 
with non-steroidal medicinal products) are highly 
important to report as well.  
Additionally, reporting can be made where 
there is lack of efficacy or when suspected 
pharmaceutical defects are observed.  This aids in 
improving the quality of batch released medicinal 
products.  
 
Management of reports   
Once a report is received by the MMA, the 
ADR case is validated and the information is 
evaluated using a causality assessment method 
(French imputability method) and against the 
product’s Summary of Product Characteristics 
(SmPC) to identify the expectedness or not of the 
ADR.  Feedback is sent to the reporter by email or 
post and if necessary a request for follow up 
information is made. Reports are then inputted into 
Eudravigilance database and reporters’ details are 
destroyed from the local paper-based form (to 
protect confidentiality of the reporter). Staff of the 
Authority will review safety issues arising from 
these received reports internally and with national 
experts/professional associations.  
The MMA also requests modifications to be 
implemented to medicinal product information 
following safety signal detection activities by the 
EMA and the opinions adopted by its Committees.  
 
How voluntary reporting of ADRs can affect the 
marketing authorization and labelling of 
medicinal products: 
Spontaneous reporting is a system whereby 
case reports of adverse events are voluntarily 
submitted by healthcare professionals to the 
national Pharmacovigilance centre.7 Once a signal 
is successfully detected and confirmed from 
spontaneous reporting; cumulative reviews are 
carried out by the regulatory authorities to propose 
any regulatory action deemed necessary (Figure 1). 
Regulatory actions can be a change in the 
product information like in the case of Celecoxib 
(Celebrex®); where reported cases of severe serious 
skin reactions and hypersensitivity reactions lead to 
adding a general statement in section 4.4 of the 
SmPC regarding these ADRs and a warning to 
discontinue Celecoxib at the first sign of 
hypersensitivity reaction.8 Or in other cases 
withdrawal from the market like suspension of 
Valdecoxib (Bextra®) -due to increased reporting of 
severe and unpredictable cutaneous adverse 
reactions- and the withdrawal of Fusafungin 
(Locabiotal®) in April, 2016 following reports of 
hypersensitivity reactions associated with its use.9-10 
 
Risk minimisation measures (RMM) and ADRs 
RMMs are a set of activities designed to guide 
optimal use of a medicinal product in medical 
practice with the goal of supporting the provision of 
the right medicine, at the right dose, at the right 
time, to the right patient and with the right 
information and monitoring.11 RMMs are often 
based on specific issues identified from the pre- or 
post-authorisation data and from pharmacological 
principles.12 
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Figure 1: How ADR reports influence product labeling and SmPC, RMMs, regulatory action of Medicines 
Authority and trigger circulation of DHPC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Since 2009, the MMA has reviewed 505 
RMMs.13 The approved RMMs can be found from 
the MMA’s website: 
www.medicinesauthority.gov.mt/safetyinf.14 
RMMs may consist of routine risk minimisation or 
additional risk minimisation activities. Routine 
RMMs are those which apply to every medicinal 
product and they are: 12 
• Summary of product characteristics. 15 
• Package leaflet.16 
• Product labelling.16 
• Pack size.12 
• Legal status: controlling the conditions under 
which a medicinal product is prescribed or the 
conditions under which it is administered. For 
example certain medications are available 
only by a special medical prescriptions e.g.  
medicines covered by the Dangerous Drugs 
Ordinance CAP 101.17-18 
For some risks a routine approach is not 
sufficient and “additional measures” are warranted 
to improve the risk-benefit balance in the approved 
indications, these  
measures come in several forms:  
• Educational materials for healthcare 
professionals and patients such as brochures, 
checklists and patient alert cards.  
• Controlled access programmes: these restrict 
how the medicines can be prescribed or 
dispensed, they can be used only when 
prescribed by a healthcare professional with 
specific expertise and patient has 
acknowledged that he is informed of a specific 
risk before receiving a medicine e.g 
Thalidomide Celgene.19 
• Pregnancy prevention programme: These 
measures aim to ensure that women are not 
pregnant during treatment with medicinal 
products that are likely to cause harm to 
unborn child e.g Thalidomide Celgene 
Pregnancy Prevention Programme.20 
• DHPC: These are letters sent directly to 
healthcare professionals who are likely to use 
the medicine, to warn them of a new safety 
concern and to inform them of the actions to 
mitigate the risk. This safety information may 
arise from studies, clinical trials or from 
spontaneous ADR reporting as well. 
Consequently, ADR reporting is valuable in 
contributing to the formulation of these 
advices. Furthermore, DHPCs increase 
awareness of healthcare professionals about 
their role and responsibility in reporting, as 
the final section of a DHPC is a reminder for 
healthcare professionals to report and how to 
report.  A link to the ADR form is provided 
along with the contact details of the MMA 
and MAH to send the completed form. All 
archived DHPCs can be accessed from 
MMA’s website: 
www.medicinesauthority.gov.mt/dhpc. To date 
the MMA approved 201 DHPCs (Table 2).  
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Table 1: number of ADR reports received in the years (2010- Nov 2017) 13,21 
 
 
When there is a potential safety concern 
relating to the safe and effective use of a medicinal 
product including warnings or alerts or product 
recalls, the MMA will issue a letter called safety 
circular to inform healthcare professionals. These 
safety circulars are available on MMA’s website: 
www.medicinesauthority.gov.mt/safetycirculars. 
The MMA operates a notification system where 
healthcare professionals can subscribe and be 
notified by SMS and e-mail regarding safety 
concern.22  
 
Shared responsibility 
It is the responsibility of the MAH to record 
all the suspected ADRs reported by healthcare 
professionals or patients and to submit them to 
“Eudravigilance” database. For these reports  
Where the suspected ADRs occurred in Malta, 
the MMA may involve the MAH in the follow-up 
of the reports. Together the MAH and the MMA 
should collaborate to detect any duplicates of 
suspected ADR reports. 
 
Conclusion 
Since 2010 to date, MMA Pharmacovigilance 
system has received and processed 1284 of 
suspected ICRS reports. Through reporting, 
healthcare professionals make a positive 
contribution to the overall knowledge of the safety 
profile of medicines and to the national 
Pharmacovigilance system. All healthcare 
professionals are therefore encouraged to start 
reporting or continue to report to enhance and 
develop this process. MMA greatly appreciates the 
interest shown by healthcare professionals towards 
ADR reporting and acknowledges the contribution 
of busy healthcare professionals to the continued 
surveillance of the safety of medicines by 
contributing to the ADR reporting system.  
 
Year 2010 2011 2012 2013 2014 2015 2016 
Up to Nov 
2017 
Number of 
ICSR 
194 150 153 150 169 122 118 228 
Number of 
reported 
ADRs 
403 273 300 349 741 615 613 416 
% of  Non-
Serious ICSR 
12.08% 10.7% 7.8% 7.33% 12.42% 4.88% 24.58% 27.89% 
% of Serious 
ICSR 
87.92% 89.3% 92.2% 92.66% 87.57% 95.12% 75.42% 72.11% 
Most frequent 
system organ 
class 
General 
disorders and 
administratio
n site 
conditions 
General 
disorders and 
administratio
n site 
conditions 
Gastrointest
inal 
disorders 
General 
disorders 
and 
administra
tion site 
conditions 
Infections 
and 
infestations 
General 
disorders 
and 
administrat
ion site 
conditions 
General 
disorders 
and 
administrat
ion site 
conditions 
 
Most frequent 
age criteria 
18-64 18-64 12-64 20-64 20-64 20-64 18-64 18-64 
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Table 2: (Number of approved joint/DHPCs, RMMs in the period 2007- Dec 2017) 21-22 
 
           Publication   
Year  
DHPC RMM Safety Circulars 
Dec 2017 18 103 6 
2016 19 107 17 
2015 11 88 15 
2014 20 91 20 
2013 40 94 28 
2012 31 38 15 
2011 26 22 19 
2010 14 11 16 
2009 8 21 12 
2008 16 / 10 
2007 11 / 19 
2006 / / 11 
2005 / / 15 
2004 / / 4 
Total  201 505 205 
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